Novo Nordisk India
Diabetes care leader
Novo Nordisk has a 60% market share in the Rs 375-crore domestic insulin market
Novo Nordisk India is the Indian subsidiary of Novo Nordisk, a focused healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. Novo Nordisk has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. It manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Novo Nordisk India employs over 600 persons currently. It plans to triple its staff strength in four years. The company has a 60 percent market share in the Rs 375-crore domestic insulin market
In keeping with its sustained commitment to improving diabetes care in India, Novo Nordisk India launched a mobile clinic - the Improve Control Mobile Clinic in Bangalore and New Delhi. The launch of the clinic in India is part of the global control initiative by Novo Nordisk, and is directed at improving diabetes care for people from different walks of life in India.
In May 2006, it launched Levemir, a basal insulin analogue that works on the mechanism of prolonging action. The insulin is delivered to the patient through a pen like mechanism. Novo Nordisk India's FlexPen is priced at Rs 930 for a 300 ml pen, on par with other analogues in the market. Novo Nordisk India has increased its sales force that cover 30,000 doctors manning diabetic clinics in India to recommend the use of Levemir. It imports Levemir from Denmark. The company expects to capture one-fourth of India's basal insulin market this year. Novo Nordisk India has an exclusive agreement with Torrent Pharma for the manufacture of insulin formulations. Torrent Pharma has been manufacturing insulin for Novo Nordisk's India requirement for more than 15 years now.
Besides marketing a portfolio of therapeutics products like NovoPen 3, Novolet and Flexpen, it has in its basket products like NovoMix 30 (premixed insulin analogue) and NovoRapid (rapid acting insulin analogue). It has a distributorship alliance with Abbot India. A recent study has shown Novo Nordisk's FlexPen's superiority over SoloStar, from Sanofi-Aventis. FlexPen is more accurate when delivering insulin than other pens like the newly launched prefilled device, SoloStar, from Sanofi-Aventis, which FlexPen significantly outperformed in both studies, according to a Novo Nordisk company release. The two studies were lead by Prof Andreas Pfützner from IKFE, Institute for Clinical Research and Development in Germany, and Dr Toshinari Asakura from the Niigata University of Pharmacy and Applied Life Sciences in Japan. The German study was published in the May 2008 issue of Diabetes Science and Technology.